ZymeworksZYME +1.64%66 Pretax Margin % is -1,924.96% as of Mar. 2026. GuruFocus rates ZYME with a GF Score™ of 66/100 and a GF Value™ of $22.34 (Fairly Valued). The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Zymeworks ranks worse than 53.65% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Zymeworks's Pre-Tax Income for the
three
months ended in Mar. 2026 was $-46.35 Mil. Zymeworks's Revenue for the
three
months ended in Mar. 2026 was $2.41 Mil. Therefore, Zymeworks's pretax margin for the quarter that ended in Mar. 2026 was -1,924.96%.
The historical rank and industry rank for Zymeworks's Pretax Margin % or its related term are showing as below:
ZYME'
s Pretax Margin % Range Over the Past 10 Years
Min: -795.95 Med: -154.85 Max: 32.79
Current: -127.94
ZYME's Pretax Margin % is ranked worse than 53.65% of 945
companies
in the Biotechnology industry
Industry Median: -90.63
vs ZYME: -127.94
Zymeworks (NAS:ZYME) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Zymeworks Pretax Margin % Related Terms
Zymeworks Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Zymeworks's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZYME vs SRPT, BCAX, INVA: Pretax Margin % Comparison
For the Biotechnology subindustry, Zymeworks's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zymeworks Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zymeworks's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Zymeworks's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zymeworks (ZYME) has a Pretax Margin % of -1,924.96% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Zymeworks and its competitors. According to the industry distribution chart, Zymeworks ranks #507 out of 945 companies in the Biotechnology industry, placing it in the top 53.7%.
Is Zymeworks' Pretax Margin % too high?
Zymeworks' current Pretax Margin % is -1,924.96%. Based on the distribution chart, Zymeworks ranks #507 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Zymeworks has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zymeworks' Pretax Margin % compare to SRPT and BCAX?
According to the Biotechnology industry distribution chart, Zymeworks ranks #507 out of 945 companies for Pretax Margin %. This places Zymeworks in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Zymeworks and its competitors. Zymeworks's current Pretax Margin % is -1,924.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zymeworks stock overvalued right now?
Based on GuruFocus' analysis, Zymeworks (ZYME) is currently considered Fairly Valued. The stock's GF Value™ is $22.34, compared to a current price of $24.13 — trading 8% above its estimated fair value. The current Pretax Margin % is -1,924.96%. Zymeworks' overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Zymeworks (ZYME), the current Pretax Margin % is -1,924.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zymeworks (ZYME) Overvalued in 2026?
Based on GuruFocus' analysis, Zymeworks stock appears to be overvalued.
The current stock price of $24.13 is trading 8% above its estimated GF Value™ of $22.34.
GuruFocus considers Zymeworks to be Fairly Valued.
Key valuation signals for ZYME:
Pretax Margin %: -1,924.96%
GF Value™: $22.34 vs. price of $24.13 (8% above fair value)
No single metric tells the full story. See the ZYME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
66GF Score
Get the complete analysis for ZYME
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZYME has been successfully added to your 
